Carisoprodol and Meprobamate, Urine, Quantitative
Also known as: CARIS U
Use
The Carisoprodol and Meprobamate, Urine, Quantitative test is utilized predominantly for confirming presumptive drug screening results, assessing compliance, or monitoring therapeutic doses. It aids in the detection of both Carisoprodol and its metabolite Meprobamate in the urine. This quantification can be helpful in managing patient care and tailoring individual treatment plans, especially in the context of substance misuse or therapeutic drug management. Its design is for clinical purposes only, implying that it is not suitable or validated for forensic purposes.
Special Instructions
Not provided.
Limitations
The absence of anticipated drugs or drug metabolites can signal non-compliance, improper specimen collection timing relative to drug administration, inadequate drug absorption, or possible sample dilution/adulteration. The test's validity hinges on concentrations exceeding the specified cutoff to be reported as positive. It is not applicable for forensic use. Analytical or technical limitations inherent to the assay could restrict its interpretive capacity, which necessitates direct laboratory consultation for further clarification on interpretive questions.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
Carisoprodol
AnalyteMeprobamate
Analyte
LOINC Codes
- 10979-3 - Carisoprodol Ur-mCnc
- 3755-6 - Meprobamate Ur-mCnc
- 10979-3 - Carisoprodol Ur-mCnc
- 3755-6 - Meprobamate Ur-mCnc
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
2 mL
Minimum Volume
0.7 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect random urine.
Storage Instructions
Refrigerated.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 weeks |
| Refrigerated | 3 weeks |
| Frozen | 3 weeks |
Other tests from different labs that may be relevant